VYGR Stock Chart & Stats
$63.00
$0.00(0.00%)
At close: 4:00 PM EDT
$63.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$53.00 - $94.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$3.17B
Enterprise Value$122.74
Total Cash (Recent Filing)$141.48M
Total Debt (Recent Filing)$34.57M
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding60,421,288
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.18
Price to Sales (P/S)5.71
P/FCF Ratio-1.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$294.97Price Target Upside368.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform & BBB DeliveryIdentification of ALPL as a mediator of IV-to-CNS transport is a durable platform strength. It supports systemic, one-time dosing with broad CNS distribution, lowering translational risk versus unknown delivery mechanisms and giving a repeatable technical edge for neurological gene therapies.
IND Clearance & Clinical PlanRegulatory clearance to begin human trials is a structural milestone that shifts program risk profile. An active clinical path enables human safety and biomarker data generation, de-risks development steps, and creates durable optionality for partnerships, milestones and future capital events.
Conservative LeverageLow debt provides durable financial flexibility for a pre-revenue biotech. Limited fixed obligations reduce near-term insolvency risk, making equity or milestone-based financing the main lever and preserving capacity to fund R&D or pursue partnerships without high interest burdens.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this scale creates persistent funding need. Over months this forces reliance on external capital, increases dilution risk, constrains the ability to advance multiple programs, and heightens execution risk if markets or partners delay financing.
Deep UnprofitabilityVery large negative net margins show operating spend far exceeds high gross profit, reflecting R&D intensity without commercial revenue. Continued losses erode equity and returns, limiting resilience to setbacks and raising the bar for future non-dilutive funding or self-sustaining operations.
Authorized Shares ExpansionNear-doubling authorized shares is a structural governance change that increases potential dilution capacity. While it provides financing flexibility, it signals anticipated equity raises and can dilute shareholder economics over time if used to fund continuing cash burn or partner-less development.
Voyager Therapeutics News
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $53.00 and its highest was $94.00 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $3.17B.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 98 days.
How were Voyager Therapeutics’s earnings last quarter?
Currently, no data Available
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 60,421,288 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Voyager Therapeutics?
Currently, no hedge funds are holding shares in MX:VYGR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$294.97 (368.21% Upside)
$294.97 (368.21% Upside)
Blogger Sentiment
Bullish
MX:VYGR Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.91%
Trailing 12-Months
Company Description
Voyager Therapeutics
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
VYGR Stock 12 Month Forecast
Average Price Target
$294.97
▲(368.21% Upside)